Cargando…

Pooled Analysis of Real-World Evidence Supports Anti-CGRP mAbs and OnabotulinumtoxinA Combined Trial in Chronic Migraine

OnabotulinumtoxinA, targeting the CGRP machinery, has been approved for the last two decades for chronic migraine prevention. The recently approved monoclonal antibodies (mAbs) directed towards the calcitonin gene-related peptide (CGRP) pathway open a new age for chronic migraine control. However, s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Scuteri, Damiana, Tonin, Paolo, Nicotera, Pierluigi, Vulnera, Marilù, Altieri, Giuseppina Cristina, Tarsitano, Assunta, Bagetta, Giacinto, Corasaniti, Maria Tiziana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9413678/ https://www.ncbi.nlm.nih.gov/pubmed/36006191 http://dx.doi.org/10.3390/toxins14080529

Ejemplares similares

Role of CGRP pathway polymorphisms in migraine: a systematic review and impact on CGRP mAbs migraine therapy
por: Scuteri, Damiana, et al.
Publicado: (2021)

Safety of Onabotulinumtoxin A in Chronic Migraine: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
por: Corasaniti, Maria Tiziana, et al.
Publicado: (2023)

Dementia and COVID-19: A Case Report and Literature Review on Pain Management
por: Scuteri, Damiana, et al.
Publicado: (2022)

Bergamot rehabilitation AgaINst agitation in dementia (BRAINAID): Study protocol for a randomized, double‐blind, placebo‐controlled trial to assess the efficacy of furocoumarin‐free bergamot loaded in a nanotechnology‐based delivery system of the essential oil in the treatment of agitation in elderly affected by severe dementia
por: Scuteri, Damiana, et al.
Publicado: (2021)

Pattern of treatment of behavioural and psychological symptoms of dementia and pain: evidence on pharmacoutilization from a large real-world sample and from a centre for cognitive disturbances and dementia
por: Scuteri, Damiana, et al.
Publicado: (2020)

New Trends in Migraine Pharmacology: Targeting Calcitonin Gene–Related Peptide (CGRP) With Monoclonal Antibodies
por: Scuteri, Damiana, et al.
Publicado: (2019)

Pharmacological Treatment of Pain and Agitation in Severe Dementia and Responsiveness to Change of the Italian Mobilization–Observation–Behavior–Intensity–Dementia (I-MOBID2) Pain Scale: Study Protocol
por: Scuteri, Damiana, et al.
Publicado: (2022)

Effect of genotype on individual response to the pharmacological treatment of glaucoma: a systematic review and meta-analysis
por: Scuteri, Damiana, et al.
Publicado: (2023)

ROBOCOP (ROBOtic Care of Poststroke Pain): Study Protocol for a Randomized Trial to Assess Robot-Assisted Functional and Motor Recovery and Impact on Poststroke Pain Development
por: Pignolo, Loris, et al.
Publicado: (2022)

Editorial: “Novel Pain Therapeutics: From Basic Research to Clinical Translation and Rehabilitation”
por: Scuteri, Damiana, et al.
Publicado: (2021)

Transgenic Mice for the Translational Study of Neuropathic Pain and Dystonia
por: Scuteri, Damiana, et al.
Publicado: (2022)

Opioids in Post-stroke Pain: A Systematic Review and Meta-Analysis
por: Scuteri, Damiana, et al.
Publicado: (2020)

Effects of Aging on Formalin-Induced Pain Behavior and Analgesic Activity of Gabapentin in C57BL/6 Mice
por: Scuteri, Damiana, et al.
Publicado: (2020)

Combination CGRP monoclonal antibody and onabotulinumtoxinA treatment for preventive treatment in chronic migraine
por: Ailani, Jessica, et al.
Publicado: (2021)

OnabotulinumtoxinA Add-On to Monoclonal Anti-CGRP Antibodies in Treatment-Refractory Chronic Migraine
por: Argyriou, Andreas A., et al.
Publicado: (2022)

Pain Assessment and Treatment in Dementia at the Time of Coronavirus Disease COVID-19
por: Scuteri, Damiana, et al.
Publicado: (2020)

Neuropharmacology of the Neuropsychiatric Symptoms of Dementia and Role of Pain: Essential Oil of Bergamot as a Novel Therapeutic Approach
por: Scuteri, Damiana, et al.
Publicado: (2019)

Diabetic retinopathy and age-related macular degeneration: a survey of pharmacoutilization and cost in Calabria, Italy
por: Scuteri, Damiana, et al.
Publicado: (2019)

Effect of Gabapentin in a Neuropathic Pain Model in Mice Overexpressing Human Wild-Type or Human Mutated Torsin A
por: Scuteri, Damiana, et al.
Publicado: (2021)

Exploitation of Thermal Sensitivity and Hyperalgesia in a Mouse Model of Dystonia
por: Scuteri, Damiana, et al.
Publicado: (2021)

Efficacy of Essential Oils in Relieving Cancer Pain: A Systematic Review and Meta-Analysis
por: Corasaniti, Maria Tiziana, et al.
Publicado: (2023)

Persistence to anti-CGRP monoclonal antibodies and onabotulinumtoxinA among patients with migraine: a retrospective cohort study
por: Charleston, Larry, et al.
Publicado: (2023)

Evidence for accuracy of pain assessment and painkillers utilization in neuropsychiatric symptoms of dementia in Calabria region, Italy
por: Scuteri, Damiana, et al.
Publicado: (2018)

Role of 5-HT1A Receptor in the Anxiolytic-Relaxant Effects of Bergamot Essential Oil in Rodent
por: Rombolà, Laura, et al.
Publicado: (2020)

Efficacy of Essential Oils in Pain: A Systematic Review and Meta-Analysis of Preclinical Evidence
por: Scuteri, Damiana, et al.
Publicado: (2021)

Pharmacokinetic Interactions between Herbal Medicines and Drugs: Their Mechanisms and Clinical Relevance
por: Rombolà, Laura, et al.
Publicado: (2020)

Preclinical Characterization of Antinociceptive Effect of Bergamot Essential Oil and of Its Fractions for Rational Translation in Complementary Therapy
por: Scuteri, Damiana, et al.
Publicado: (2022)

Long-Term Management of Migraine With OnabotulinumtoxinA (Botox) vs Calcitonin Gene-Related Peptide Antibodies (Anti-CGRP)
por: Pallapothu, Manoj R, et al.
Publicado: (2023)

OnabotulinumtoxinA in the treatment of neurogenic bladder
por: Gulamhusein, Aziz, et al.
Publicado: (2012)

OnabotulinumtoxinA for the treatment of overactive bladder
por: Cox, Lindsey, et al.
Publicado: (2014)

Botox (onabotulinumtoxinA) mechanism of action
por: Brin, Mitchell F., et al.
Publicado: (2023)

OnabotulinumtoxinA effects on trigeminal nociceptors
por: Moore, Ashley A, et al.
Publicado: (2023)

Aromatherapy in Stroke Patients: Is it Time to Begin?
por: Contrada, Marianna, et al.
Publicado: (2021)

Triptan efficacy does not predict onabotulinumtoxinA efficacy but improves with onabotulinumtoxinA response in chronic migraine patients
por: Eren, Ozan E., et al.
Publicado: (2020)

Anxiolytic-Like Effects of Bergamot Essential Oil Are Insensitive to Flumazenil in Rats
por: Rombolà, Laura, et al.
Publicado: (2019)

Effects of Palmitoylethanolamide (PEA) on Nociceptive, Musculoskeletal and Neuropathic Pain: Systematic Review and Meta-Analysis of Clinical Evidence
por: Scuteri, Damiana, et al.
Publicado: (2022)

Analgesic Characteristics of NanoBEO Released by an Airless Dispenser for the Control of Agitation in Severe Dementia
por: Scuteri, Damiana, et al.
Publicado: (2022)

Progress in the Treatment of Migraine Attacks: From Traditional Approaches to Eptinezumab
por: Scuteri, Damiana, et al.
Publicado: (2021)

Antispasmodic Effect of Bergamot Essential Oil on Rat Isolated Gut Tissues
por: Rombolà, Laura, et al.
Publicado: (2022)

Pregnancy outcomes following exposure to onabotulinumtoxinA
por: Brin, Mitchell F., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_5mj35lp42ea055aqdm2vo1j4s5